共 50 条
- [35] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment Clinical Pharmacokinetics, 2020, 59 : 747 - 755
- [38] Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study JOURNAL OF CROHNS & COLITIS, 2021, 15 : S321 - S322
- [40] Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency Journal of Clinical Immunology, 2022, 42 : 512 - 513